0.42(2.79%) Volume: 695,151 4:00PM EST| Market Cap : 1.13 B | Enterprise Value : 872.89 M | P/E (TTM) : | P/B : 3.87 |
|---|
NAS:INSM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:INSM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 1.82 |
INSM's Cash-to-Debt is ranked lower than
72% of the 1078 Companies in the Global Biotechnology industry. ( Industry Median: 64.02 vs. INSM: 1.82 ) Ranked among companies with meaningful Cash-to-Debt only. |
INSM'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.86 Med: 10.2 Max: No Debt Current: 1.82 |
| Debt-to-Equity | 1.07 |
INSM's Debt-to-Equity is ranked lower than
80% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 0.28 vs. INSM: 1.07 ) Ranked among companies with meaningful Debt-to-Equity only. |
INSM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.75 Med: 0.14 Max: 3.85 Current: 1.07 |
| Debt-to-EBITDA | -1.14 |
INSM's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 2.04 vs. INSM: -1.14 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
INSM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.14 Med: -0.19 Max: 0 Current: -1.14 |
| Piotroski F-Score: 2 |
|
| Altman Z-Score: -1.08 |
|
| Beneish M-Score: -4.60 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| ROE % | -79.31 |
INSM's ROE % is ranked lower than
66% of the 989 Companies in the Global Biotechnology industry. ( Industry Median: -42.82 vs. INSM: -79.31 ) Ranked among companies with meaningful ROE % only. |
INSM'
s ROE % Range Over the Past 10 Years
Min: -361.62 Med: -44.96 Max: 195.47 Current: -79.31 |
| ROA % | -47.66 |
INSM's ROA % is ranked lower than
61% of the 1084 Companies in the Global Biotechnology industry. ( Industry Median: -34.77 vs. INSM: -47.66 ) Ranked among companies with meaningful ROA % only. |
INSM'
s ROA % Range Over the Past 10 Years
Min: -129.17 Med: -37.18 Max: 180.06 Current: -47.66 |
| ROC (Joel Greenblatt) % | -1862.85 |
INSM's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1036 Companies in the Global Biotechnology industry. ( Industry Median: -521.46 vs. INSM: -1862.85 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
INSM'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -720550 Med: -2254.29 Max: -1133.76 Current: -1862.85 |
| 3-Year Revenue Growth Rate | -100.00 |
INSM's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 651 Companies in the Global Biotechnology industry. ( Industry Median: 1.10 vs. INSM: -100.00 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
INSM'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: -14.3 Max: 481.9 Current: -100 |
| 3-Year EBITDA Growth Rate | -21.10 |
INSM's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 802 Companies in the Global Biotechnology industry. ( Industry Median: 4.60 vs. INSM: -21.10 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
INSM'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: 7.7 Max: 43.7 Current: -21.1 |
| 3-Year EPS without NRI Growth Rate | -21.20 |
INSM's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 763 Companies in the Global Biotechnology industry. ( Industry Median: 5.70 vs. INSM: -21.20 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
INSM'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: 8.6 Max: 59.5 Current: -21.2 |
| Leon Cooperman 155,000 sh (+3.33%) | Steven Cohen Sold Out Louis Moore Bacon Sold Out Paul Tudor Jones 9,022 sh (-74.71%) Jim Simons 36,487 sh (-34.71%) |
| Paul Tudor Jones 15,066 sh (+66.99%) | Jim Simons Sold Out Leon Cooperman 98,000 sh (-36.77%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:ESPR, SZSE:002030, BOM:539268, NAS:ARNA, NAS:CORT, NYSE:CBM, NAS:AIMT, NAS:ENTA, HKSE:06826, NAS:MYOK, NAS:ACAD, NAS:DNLI, NAS:ICPT, XMCE:ALM, NAS:XLRN, SZSE:002287, NAS:GBT, NAS:SPPI, NAS:MDGL, XKRX:095700 » details | |
| Traded in other countries: | IM8N.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 3.87 |
INSM's PB Ratio is ranked lower than
53% of the 962 Companies in the Global Biotechnology industry. ( Industry Median: 4.10 vs. INSM: 3.87 ) Ranked among companies with meaningful PB Ratio only. |
INSM'
s PB Ratio Range Over the Past 10 Years
Min: 0.45 Med: 3.94 Max: 105 Current: 3.87 |
| EV-to-EBIT | -3.16 |
INSM's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies in the Global Biotechnology industry. ( Industry Median: 22.17 vs. INSM: -3.16 ) Ranked among companies with meaningful EV-to-EBIT only. |
INSM'
s EV-to-EBIT Range Over the Past 10 Years
Min: -215.2 Med: -7.1 Max: 163.9 Current: -3.16 |
| EV-to-EBITDA | -3.20 |
INSM's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies in the Global Biotechnology industry. ( Industry Median: 18.08 vs. INSM: -3.20 ) Ranked among companies with meaningful EV-to-EBITDA only. |
INSM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -256.4 Med: -7.2 Max: 317.3 Current: -3.2 |
| Current Ratio | 10.06 |
INSM's Current Ratio is ranked higher than
85% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.46 vs. INSM: 10.06 ) Ranked among companies with meaningful Current Ratio only. |
INSM'
s Current Ratio Range Over the Past 10 Years
Min: 0.53 Med: 7.35 Max: 50.67 Current: 10.06 |
| Quick Ratio | 10.06 |
INSM's Quick Ratio is ranked higher than
85% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. INSM: 10.06 ) Ranked among companies with meaningful Quick Ratio only. |
INSM'
s Quick Ratio Range Over the Past 10 Years
Min: 0.53 Med: 7.35 Max: 50.67 Current: 10.06 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.60 |
INSM's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 857 Companies in the Global Biotechnology industry. ( Industry Median: -13.40 vs. INSM: -16.60 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
INSM'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119 Med: -26.1 Max: -5.4 Current: -16.6 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Net-Cash | 5.72 |
INSM's Price-to-Net-Cash is ranked higher than
56% of the 613 Companies in the Global Biotechnology industry. ( Industry Median: 7.29 vs. INSM: 5.72 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
INSM'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.57 Med: 5.1 Max: 197.5 Current: 5.72 |
| Price-to-Net-Current-Asset-Value | 5.44 |
INSM's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 745 Companies in the Global Biotechnology industry. ( Industry Median: 6.45 vs. INSM: 5.44 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
INSM'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52 Med: 4.89 Max: 156.67 Current: 5.44 |
| Price-to-Tangible-Book | 4.88 |
INSM's Price-to-Tangible-Book is ranked lower than
51% of the 894 Companies in the Global Biotechnology industry. ( Industry Median: 5.32 vs. INSM: 4.88 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
INSM'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.51 Med: 4.68 Max: 85 Current: 4.88 |
| Earnings Yield (Greenblatt) % | -31.80 |
INSM's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 1081 Companies in the Global Biotechnology industry. ( Industry Median: -7.73 vs. INSM: -31.80 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
INSM'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8315.3 Med: -12 Max: 8748.9 Current: -31.8 |
| EPS (TTM) $ | -3.91 |
|---|---|
| Beta | 2.46 |
| Volatility | 52.04% |
| 52-Week Range $ | 13.85 - 33.94 |
| Shares Outstanding (Mil) | 77.09 |
| Dec18 | Dec19 | Dec20 | Dec21 | |
|---|---|---|---|---|
| Revenue (Mil $) | 4 | 57 | 199 | 463 |
| EBIT (Mil $) | -303 | -258 | -145 | 115 |
| EBITDA (Mil $) | -297 | -242 | -199 | |
| EPS ($) | -4.15 | -3.36 | -1.90 | 1.03 |
| EPS without NRI ($) | -4.15 | -3.36 | -1.90 | 1.03 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | |||
| Dividends per Share ($) | ||||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP